Abbott Laboratories

New York Stock Exchange
Back to all articles
Somewhat Bullish +45

Equities Analysts Offer Predictions for ABT FY2026 Earnings

AI-generated analysis

📉 Erste Group Bank lowered its FY2026 EPS forecast for Abbott Laboratories to $5.47 per share from a previous estimate of $5.48.

📈 JPMorgan Chase increased its price target on ABT shares to $120.00 and assigned an 'overweight' rating in a recent research note.

💰 Abbott Laboratories reported quarterly earnings of $1.31 per share, surpassing the consensus estimate of $1.28 by $0.03.

📊 The company generated revenue of $12.51 billion for the quarter, marking a 13% increase compared to the same period last year.

🏦 Freemont Management S.A. significantly increased its stake in Abbott Laboratories by 197.2% during the fourth quarter.

💵 The company declared a quarterly dividend of $0.63 per share, payable on August 17th to shareholders of record on July 15th.

📉 Goldman Sachs reduced its price target from $121.00 to $113.00 while maintaining a 'buy' rating on the stock.

🎯 The consensus analyst price target for Abbott Laboratories is currently set at $118.61 with a 'Moderate Buy' overall rating.

📈 Abbott Laboratories has established full-year 2026 earnings guidance ranging from $5.45 to $5.60 per share.

👔 Director Daniel J. Starks purchased 10,000 shares of the company's stock for a total transaction value of $926,500.

Bullish Signals
  • Abbott Laboratories beat quarterly earnings expectations with $1.31 EPS compared to the consensus of $1.28.
  • The company achieved a strong revenue growth of 13% year-over-year, reaching $12.51 billion for the quarter.
  • JPMorgan Chase raised its price target to $120 and assigned an 'overweight' rating, indicating bullish sentiment.
  • Freemont Management S.A. increased its holdings by 197.2%, signaling strong institutional confidence in the stock.
  • Thrivent Financial for Lutherans boosted its stake by 24.3%, adding over $30 million to its position.
  • The company maintains a healthy dividend yield of 2.5% with an annualized payout of $2.52 per share.
  • Abbott Laboratories reported a solid return on equity of 17.65% and a net margin of 11.65%.
Risk Factors
  • Erste Group Bank reduced its FY2026 EPS estimate to $5.47, slightly below the consensus forecast of $5.48.
  • Goldman Sachs lowered its price target from $121.00 to $113.00, reflecting a more cautious valuation outlook.
  • Raymond James Financial cut its price target significantly from $130.00 to $115.00 despite maintaining an 'outperform' rating.
  • Barclays decreased its price target from $144.00 to $143.00, indicating a narrowing of the upside potential.
  • Quarterly revenue of $12.51 billion slightly missed analyst expectations of $12.52 billion.
Full Analysis
Equities analysts have issued mixed signals regarding Abbott Laboratories (NYSE:ABT) ahead of its fiscal year 2026 earnings, with Erste Group Bank reducing its full-year EPS estimate to $5.47 from $5.48 and Raymond James Financial cutting its price target to $115. Conversely, JPMorgan Chase raised its objective to $120 with an 'overweight' rating, while Goldman Sachs lowered its target to $113 but maintained a 'buy' stance. The consensus rating remains a 'Moderate Buy' with a collective price target of $118.61. Abbott Laboratories recently reported strong quarterly results, posting $1.31 in earnings per share which beat the consensus estimate of $1.28. Revenue reached $12.51 billion, representing a 13% year-over-year increase, though it slightly missed analyst expectations of $12.52 billion. The company achieved an 11.65% net margin and a return on equity of 17.65%, with guidance for the full fiscal year 2026 set between $5.45 and $5.60 per share. Institutional ownership remains robust at 75.18%, highlighted by significant stake increases from Freemont Management S.A., which raised its holdings by 197.2% to own over 10,000 shares, and Thrivent Financial for Lutherans, which boosted its position by 24.3%. Company insiders also demonstrated confidence, with Director Daniel J. Starks purchasing $926,500 worth of stock and CFO Philip P. Boudreau acquiring an additional $201,300 in shares during the first quarter.